U.S. markets closed
  • S&P Futures

    4,526.00
    +1.75 (+0.04%)
     
  • Dow Futures

    34,933.00
    +23.00 (+0.07%)
     
  • Nasdaq Futures

    15,044.75
    +11.25 (+0.07%)
     
  • Russell 2000 Futures

    2,060.10
    +0.90 (+0.04%)
     
  • Crude Oil

    86.00
    -0.96 (-1.10%)
     
  • Gold

    1,842.80
    -0.40 (-0.02%)
     
  • Silver

    24.17
    -0.06 (-0.23%)
     
  • EUR/USD

    1.1365
    +0.0018 (+0.16%)
     
  • 10-Yr Bond

    1.8270
    -0.0380 (-2.04%)
     
  • Vix

    23.85
    +1.06 (+4.65%)
     
  • GBP/USD

    1.3633
    +0.0021 (+0.15%)
     
  • USD/JPY

    114.1440
    -0.2090 (-0.18%)
     
  • BTC-USD

    41,747.78
    -620.09 (-1.46%)
     
  • CMC Crypto 200

    989.51
    -5.24 (-0.53%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,329.34
    -137.89 (-0.50%)
     

BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing the approval of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) ORLADEYO (berotralstat) for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.

  • HAE is a disorder characterized by recurrent attacks severe swelling (angioedema). The swelling most commonly affects the arms, legs, face, intestinal tract, and airway and is usually not itchy.

  • The European Commission will review the recommendation, and a final approval decision on the marketing application is expected in the second quarter.

  • The product is approved in the U.S. and Japan.

  • Early Access to the treatment has been approved by the Medicines & Healthcare products Regulatory Agency in the U.K.

  • Price Action: BCRX shares are trading 0.2% lower at $10.45 in the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.